Mendus

.Hero-module--bg-image--2RKA9.gbi-1276703326-77MTVkVVet3mGNCQ7BWwdX:before { opacity: 1; background-image: url('/static/64ff3c5dc09358fb1f6e6ee5f4a8dcf4/e65ba/Mendus_woman-with-surfboard_darker-min-compress.jpg'); }

Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.

<picture><source type="image/webp" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/dbb21/disarming-cancer-threat.webp 151w,/static/f6777646b01027295d9a7ee75dea7c96/8cdf4/disarming-cancer-threat.webp 302w,/static/f6777646b01027295d9a7ee75dea7c96/39272/disarming-cancer-threat.webp 603w" sizes="(min-width: 603px) 603px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 603px) 603px, 100vw" decoding="async" loading="lazy" src="/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/bedb7/disarming-cancer-threat.jpg 151w,/static/f6777646b01027295d9a7ee75dea7c96/8f82e/disarming-cancer-threat.jpg 302w,/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg 603w" alt="&lt;p&gt;Middle aged man running in a field of grass, surrounded by mountains.&lt;/p&gt;
"/></picture>
Gaining the 
upper handToday, tumor recurrence causes the vast majority of cancer-related deaths. We want to change this by designing new therapeutic options that tip the balance in favor of the immune system.
What we do

<picture><source type="image/webp" srcSet="/static/aafedabe406814250bbca33ccd38dca0/5b094/ways-to-make-dif.webp 225w,/static/aafedabe406814250bbca33ccd38dca0/ecbb3/ways-to-make-dif.webp 450w,/static/aafedabe406814250bbca33ccd38dca0/10d3d/ways-to-make-dif.webp 900w" sizes="(min-width: 900px) 900px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 900px) 900px, 100vw" decoding="async" loading="lazy" src="/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg" srcSet="/static/aafedabe406814250bbca33ccd38dca0/51892/ways-to-make-dif.jpg 225w,/static/aafedabe406814250bbca33ccd38dca0/ea40c/ways-to-make-dif.jpg 450w,/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg 900w" alt=""/></picture>
New ways to make a differenceWe dare to shine the light of science down new and unexplored paths to improve the course of cancer treatment.
About us

Latest newsAll news
1 September 2022Latest
Mendus to participate in upcoming conferences in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced its...
Learn more
26 August 2022
Mendus AB (publ) interim report April – June 2022
Progress made throughout the second quarter puts the company in a strong position to deliver meaningful clinical progress in the second half of 2022, with updated survival data from the ADVANCE II...
Learn more
26 August 2022
Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a...
Learn more
14 July 2022
Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established...
Learn more
23 June 2022
Immunicum Announces Corporate Rebranding and Name Change to Mendus AB
Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations. The Company’s stock to continue trading under...
Learn more
9 June 2022
Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)
Immunicum announced that it has been granted an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST).
Learn more
1 June 2022
Immunicum to Participate in Upcoming Conferences
Immunicum today announced its participation in the following upcoming conferences:...
Learn more

For investors
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors
<picture><source type="image/webp" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/7bc26/124.webp 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/5e603/124.webp 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/af8c4/124.webp 1656w" sizes="(min-width: 1656px) 1656px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1656px) 1656px, 100vw" decoding="async" loading="lazy" src="/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/1d336/124.jpg 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/8753d/124.jpg 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg 1656w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Latest presentation1 September 2022Corporate Presentation - September 2022
Financial calendar15 April 2022Publication of 2021 Annual Report
10 May 2022Annual General Meeting
10 May 2022Publication of Q1 Report
26 August 2022Publication of Q2 Report
11 November 2022Publication of Q3 Report
17 February 2023Publication of Year-end Report 2022

EventsAll events
11 November 2022
Upcoming
Publication of Q3 2022 ResultsMendus will publish the results of the third quarter of 2022 on November 11th, 2022 at 8am CET.
Learn more
October 2022Upcoming
European Society of Gynecological Oncology Congress
Initial clinical results from the ALISON trial were accepted for presentation at the European Society of Gynecological Oncology (ESGO) congress.
Learn more
September 2022Previous
Next Frontiers in Cancer Vaccines
Mendus CEO Erik Manting will present on September 28th, 2022 at 3:10 pm CET at the event organized by HollandBIO and the Oncode Institute.
Learn more
September 2022Previous
Sachs 22nd Annual Biotech in Europe Forum
The 22nd Annual Biotech in Europe Forum will take place in-person on September 21-22, 2022, at the Mövenpick Hotel in Basel, Switzerland. Mendus' CEO Erik Manting will present on September 21, 2022.
Learn more

.FullWidthImage-module--bg-image-mobile--1fPGr.FullWidthImage-module--hide-in-mobile--XC8T7.gbi--1792894973-v2sPH2o5s8dE3FA48htWQi:before { opacity: 1; background-image: url('/static/db5cac225ec6b40b3e48015942da980e/d3468/home-section-fullwidth.jpg'); }

A life-changing careerAt Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.
Careers

Changing the course of cancer treatment

Gaining the upper hand

New ways to make a difference

Latest news

Mendus to participate in upcoming conferences in September

Mendus AB (publ) interim report April – June 2022

Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group

Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)

Immunicum to Participate in Upcoming Conferences

For investors

Invest in future cancer care

Latest presentation

Financial calendar

Events

Publication of Q3 2022 Results

European Society of Gynecological Oncology Congress

Next Frontiers in Cancer Vaccines

Sachs 22nd Annual Biotech in Europe Forum

A life-changing career

Keep up to date

Gaining the
upper hand